As mutation of KRAS is the most frequent genetic alteration in pancreatic adenocarcinoma as well as in precancerous lesions such as PanIN (Pancreatic Intraepithelial neoplasia) [28], we evaluated whether miR-92a-3p also influences response of KRAS-mutated pancreatic cancer cells to cisplatin by performing loss of function experiments in PANC1 cells, a human epithelioid carcinoma cell line harboring the KRASG12D mutation. Here, KRAS is linked to pancreatic neoplasm.